Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

@article{Mease2005AdalimumabFT,
  title={Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.},
  author={Philip J Mease and Dafna D Gladman and Christopher T. Ritchlin and Eric M. Ruderman and Serge D Steinfeld and Ernest H. S. Choy and John T. Sharp and Peter A Ory and Renee J Perdok and Mark A. Weinberg},
  journal={Arthritis and rheumatism},
  year={2005},
  volume={52 10},
  pages={3279-89}
}
OBJECTIVE Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA). METHODS Patients with moderately to severely active PsA and a history of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg adalimumab or placebo subcutaneously every other week for 24 weeks. Study visits were at baseline, weeks 2 and 4, and every 4… CONTINUE READING
Highly Influential
This paper has highly influenced 16 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 246 extracted citations

Similar Papers

Loading similar papers…